[go: up one dir, main page]

EP0707585A1 - Bicyclic tetrahydro pyrazolopyridines - Google Patents

Bicyclic tetrahydro pyrazolopyridines

Info

Publication number
EP0707585A1
EP0707585A1 EP94916370A EP94916370A EP0707585A1 EP 0707585 A1 EP0707585 A1 EP 0707585A1 EP 94916370 A EP94916370 A EP 94916370A EP 94916370 A EP94916370 A EP 94916370A EP 0707585 A1 EP0707585 A1 EP 0707585A1
Authority
EP
European Patent Office
Prior art keywords
ethyl
oxo
tetrahydro
pyrazolo
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94916370A
Other languages
German (de)
English (en)
French (fr)
Inventor
Allen Jacob Duplantier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Corp SRL
Pfizer Inc
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL, Pfizer Inc filed Critical Pfizer Corp Belgium
Publication of EP0707585A1 publication Critical patent/EP0707585A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • This invention relates to a series of bicyclic tetrahydro pyrazolopyridines which are selective inhibitors of phosphodiesterase (PDE) type IV or the production of tumor necrosis factor (hereinafter TNF) and as such are useful in the treatment of asthma, arthritis, bronchitis, chronic obstructive airways disease, psoriasis, allergic rhinitis, dermatitis and other inflammatory diseases; and AIDS, septic shock and other diseases involving the production of TNF.
  • PDE phosphodiesterase
  • TNF tumor necrosis factor
  • This invention also relates to a method of using such compounds in the treatment of the above diseases in mammals, especially humans and to pharmaceutical compositions useful therefor.
  • TNF is recognized to be involved in many infectious and auto-immune diseases (W. Friers, FEBS Letters, 1991 , 285, 199). Furthermore, it has been shown that TNF is the prime mediator of the inflammatory response seen in sepsis and septic shock (C.E. Spooner et al., Clinical Immunology and Immunopathology, 1992, 62, S11 ). Summary of the Invention The present invention relates to compounds of the formula
  • R 1 is hydrogen, (C'-C 7 )alkyl, (C 2 -C 3 )alkenyl, (C 3 -C 5 )cycloalkyl or methylene (C 3 -C 5 )cycloalkyl wherein each alkyl or alkenyl group may be optionally substituted with up to two (C'-C ⁇ alkyl or trifluoromethyl groups or up to three halogens;
  • X is oxygen or two hydrogen atoms;
  • R 2 and R 3 are each independently selected from the group consisting of hydrogen, (C'-C' ⁇ alkyl, (C 1 - C ,4 )alkoxy, (C 2 -C 7 )alkenyl, a (C 4 -C 7 )heterocyclic group containing oxygen, sulphur, SO 2 or NR 5 wherein R 5 is hydrogen or (C 1 -C 4 )alkyl, or a group of the formula
  • a is an integer from 1 to 5; b and c is O or 1 ;
  • R 4 is hydrogen, hydroxy, (C 1 - C 5 )alkyl, (C 2 -C 5 )alkenyl, (C'-C ⁇ alkoxy, (C 3 -C ⁇ )cycloalkoxy, halogen, trifluoromethyl, CO 2 R 6 , CONR 6 R 7 , NR 6 R 7 , NO 2 or SO 2 NR 6 R 7 wherein R ⁇ and R 7 are each independently hydrogen or (C 1 -C 4 )alkyl; wherein Z is oxygen, sulphur, SO 2 or NR 8 wherein R 8 is hydrogen or (C'-C ⁇ alkyl; and Y is (C'-C 5 )alkylene or (C 2 -C 6 )alkenyl optionally substituted with up to two (C'-C 7 )alkyl or (C 3 -C 7 )cycloalkyl groups; or a group of
  • R 9 is (C'-C ⁇ alkyl; wherein each said alkyl, alkenyl, cycloalkyl, alkoxyalkyl or heterocyclic group may be optionally substituted with one to fourteen, preferably one to five, of the group consisting of (C 1 - C 2 )alkyl, trifluoromethyl or halogen with the proviso that when R 1 is ethyl and R 2 is 4- methylphenyl, R 3 cannot be hydrogen, methyl, phenyl, 4-fluorophenyl or 2-pyridyl and with the proviso that when R 2 is 4-methylphenyl and R 3 is 4-fluorophenyl, R 1 cannot be phenyl, methyl or n-propyl and with the proviso that when R 1 is ethyl and R 2 is phenyl, R 3 cannot be 4-chlorophenyl, 4-fluorophenyl or
  • R 1 is (C 1 -C 3 )alkyl and R 2 and R 3 are each independently selected from the group consisting of (C 3 -C )cycloalkyl, (C 4 -C 7 )heterocyclic group containing SO 2 or a group of the formula
  • a is an integer from 1 to 5 and R 4 is hydrogen, hydroxy, (C'-C ⁇ alkyl, (C 1 -
  • the invention relates to a compound of formula I wherein R 1 is ethyl or isopropyl; R 2 is phenyl, 2-methylphenyl, 3-methylphenyl, 2- methoxyphenyl, 3-methoxyphenyl or 3-trifluoromethylphenyl and R 3 is cyclobutyl, cyclopentyl, cyclohexyl, 3-sulfolanyl, 4-fluorophenyl or 3,4-dichlorophenyl.
  • the present invention further relates to a pharmaceutical composition for the inhibition of phosphodiesterase (PDE) type IV and the production of tumor necrosis factor (TNF) comprising a pharmaceutically effective amount of a compound according to formula I and the pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier.
  • PDE phosphodiesterase
  • TNF tumor necrosis factor
  • the present invention further relates to a method for the inhibition of phosphodiesterase (PDE) type IV and the production of tumor necrosis factor (TNF) comprising administering to a patient an effective amount of a compound according to formula I and the pharmaceutically acceptable salts thereof.
  • PDE phosphodiesterase
  • TNF tumor necrosis factor
  • the present invention further relates to a method of treating an inflammatory condition in mammals which comprises administering to said mammal an antiinflammatory amount of a compound of the formula I and the pharmaceutically acceptable salts thereof.
  • the present invention further relates to a pharmaceutical composition for the treatment of asthma, arthritis, bronchitis, chronic obstructive airways disease, psoriasis, allergic rhinitis, dermatitis and other inflammatory diseases, AIDS, septic shock and other diseases involving the production of TNF comprising a pharmaceutically effective amount of a compound according to formula I and the pharmaceutically acceptable salts thereof together with a pharmaceutically acceptable carrier.
  • This invention further relates to a method of treating or preventing a condition selected from the group consisting of asthma, arthritis, bronchitis, chronic obstructive airways disease, psoriasis, allergic rhinitis, dermatitis and other inflammatory diseases, AIDS, septic shock and other diseases involving the production of TNF comprising administering to a patient an effective amount of a compound according to formula I and the pharmaceutically acceptable salts thereof.
  • halogen as used herein, unless otherwise indicated, includes chloro, fluoro and bromo.
  • alkyl, alkoxy and alkenyl groups referred to herein may be straight chained or if comprising three or more carbons may be straight chained, branched, cyclic or a combination of cyclic and branched or straight chained moieties.
  • the "inflammatory diseases” which can be treated according to this invention include, but are not limited to asthma, chronic obstructive pulmonary disease, bronchitis and arthritis.
  • R 1 , R 2 and R 3 as used herein, unless otherwise indicated, are as defined above with reference to formula I.
  • aryl is a group of the formula II by reacting IV with an aryl halide neat in the presence of copper power and potassium carbonate.
  • Suitable aryl halides include 1-iodo- or 1-bromo- 4- methoxybenzene, 3-methoxybenzene, 2-methoxybenzene, 3-methylbenzene, 4- methylbenzene, 2-methylbenzene, 3-trifluoromethylbenzene, 2-trifluoromethylbenzene, 3,4-dimethoxybenzeneor3-cyclopentoxy-4-methoxybenzene.
  • the reaction temperature will generally be in the range of about 110°C to about 170°C, preferably about 150°C, for a time period of about 14 hours to about 22 hours, preferably about 18 hours, under inert reaction conditions.
  • R 1 halide is added to a suspension of magnesium in an anhydrous aprotic solvent.
  • the reaction mixture is heated to reflux until all the magnesium is consumed and thereafter cooled to a temperature between about -15°C to about 15°C, preferably about 0°C.
  • the N-(aryl)-2-pyrrolidone compound of formula V is then added and the reaction mixture is warmed to room temperature while being stirred for a time period between about 1.5 hours to about 2.5 hours, preferably about 2 hours.
  • Suitable alkyl halides include bromomethane, bromoethane or bromopropane.
  • the preferred anhydrous aprotic solvent is anhydrous ether.
  • the above precipitate is converted to the corresponding 1 ,2,5,6- tetrahydropyridine compound of formula VI by dispersing the precipitate in a mixture of a non-polar aprotic solvent and base.
  • a non-polar aprotic solvent and base Upon vigorous stirring, ethyl oxalyl chloride is added and the reaction mixture is heated to reflux for a time period between about 1.5 hours to about 4.5 hours, preferably about 3.0 hours.
  • the preferred non-polar aprotic solvent is benzene and the preferred base is sodium hydroxide. The solvents are removed and the resulting residue is treated with a solution of sodium alkoxide in ethanol.
  • the compound of formula VI is converted to the corresponding 3-methoxy-1 ,2,5,6-tetrahydropyridine compound VII by heating to reflux a reaction mixture of VI and 3-methyl-1-p-tolyltriazene in an aprotic solvent.
  • the preferred aprotic solvent is 1 ,2-dichloroethane.
  • the time period for the reaction is between about 30 minutes to about 120 minutes, preferably about 45 minutes.
  • the 1 ,2,5,6-tetrahydropyridine compound of formula VIII is converted to the corresponding compound of formula IX by reacting VIII with a hydrazine hydrochloride and sodium alkoxide in an anhydrous polar protic solvent.
  • the preferred sodium alkoxide is sodium methoxide and the preferred anhydrous polar protic solvent is anhydrous ethanol.
  • the reaction mixture is heated to reflux for a time period between about 9 hours to about 15 hours, preferably about 12 hours.
  • the 1 ,2,5,6-tetrahydro-pyridine compound VIII is converted to the corresponding compound of formula IX by reacting VII) with hydrazinobenzoic acid in an anhydrous polar protic solvent, preferably ethanol.
  • the reaction mixture is heated to reflux for a time period between about 16 hours to about 24 hours, preferably about 20 hours.
  • the compound IX so formed may be further reacted to give the corresponding 1-(4-benzamide)-7-oxo-4,5,6,7-tetrahydro-1 H- pyrazolo[3,4-c]pyridine compound by reacting IX with sodium methoxide in a polar protic solvent, preferably methanol, for a time period between about 15 minutes to about 45 minutes, preferably 30 minutes.
  • a polar protic solvent preferably methanol
  • the polar protic solvent is removed under reduced pressure, the solid residue is suspended in a non-polar aprotic solvent, perferably benzene, and thereafter, the non-polar solvent is removed under reduced pressure.
  • the resulting dry solid is suspended in cold ether and treated with oxalyl chloride and N,N-dimethylformamide and allowed to stir for a time period between about 30 minutes to about 90 minutes, preferably 60 minutes..
  • the solvent is then removed and the crude residue is dissolved in dry tetrahydrofuran.
  • the resulting solution is added dropwise to stirred ammonium hydroxide at a temperature between about -10°C to about 10°C, preferably 0°C.
  • the 1 ,2,5,6-tetrahydropyridine compound of formula VIII is converted to the corresponding compound of formula IX by reacting VIM with a hydrazine hydrochloride in a polar protic solvent, preferably methanol.
  • a polar protic solvent preferably methanol.
  • the reaction mixture is heated to a temperature between about 70 °C to about 110°C, preferably about 90°C, under a gentle stream of nitrogen until all of the solvent is removed.
  • the neat mixture is then heated to a temperature between about 120°C to about 180°C, preferably about 150°C, for a time period between about 30 minutes to about 90 minutes, preferably 60 minutes.
  • the compounds so formed of formula IX may be converted to the corresponding 6-R 2 -4,5,6,7-tetrahydro-7-oxo-1 H-pyrazolo [3,4-c]pyridine compound, wherein R 2 is other than the group of formula II, by reacting a solution of IX in a polar aprotic solvent, preferably acetonitrile, with a solution of ammonium cerium (IV) nitrate in water at a temperature between about -15°C to about 15°C, preferably about 0°C, for a time period between about 20 minutes to about 50 minutes, preferably about 35 minutes. Upon completion of the reaction, the mixture is diluted with water and extracted with ethyl acetate.
  • a polar aprotic solvent preferably acetonitrile
  • the combined organics are then washed with saturated sodium bicarbonate followed by sodium sulfite.
  • the compound so formed in a polar aprotic solvent, preferably tetrahydrofuran, is treated with sodium hydride, heated to reflux and stirred for a time period between about 30 minutes to about 60 minutes, preferably 45 minutes.
  • the reaction mixture is cooled to a temperature between about 20°C to about 30°C, preferably about 25°C, and an alkyl halide of formula R 2 halide, wherein R 2 is as defined with reference to formula I other than a group of formula II, is added.
  • the reaction mixture is stirred and heated to reflux for a time period between about 12 hours to about 20 hours, preferably 16 hours.
  • the 2-oxo-4,5,6,7-tetrahydro-1 H-pyrazolo[3,4- c]pyridine compound IX is converted to the corresponding compound of formula X by reacting IX with a reducing agent, preferably lithium aluminum hydride, in a non-polar aprotic solvent, preferably ether.
  • a reducing agent preferably lithium aluminum hydride
  • a non-polar aprotic solvent preferably ether.
  • the reaction is stirred for a time period between about 12 hours to about 20 hours, preferably 16 hours.
  • Water and base, preferably sodium hydroxide is then added and the reaction mixture is stirred for a time period between about 1.5 hours to about 2.5 hours, preferably 2 hours, and filtered.
  • the filtrate is concentrated to a white solid.
  • DMSO DMSO to achieve desired concentrations.
  • Final DMSO concentration in assay tube is 1 %.
  • the following are added, in order, to a 12 x 75 mm glass tube (all concentrations are given as final concentrations in assay tube).
  • iv) 25 ⁇ l PDE IV enzyme for blank, enzyme is preincubated in boiling water for 5 minutes
  • the reaction tubes are shaken and placed in a water bath (37° C) for 20 minutes, at which time the reaction is stopped by placing the tubes in a boiling water bath for 4 minutes.
  • Washing buffer 0.5 ml, 0.1 M 4-(2-hydroxyethyl)-1-piperazine- ethanesulfonic acid (HEPES)/0.1 M NaCI, pH 8.5
  • each tube is applied to an Affi-Gel 601 column (Biorad Laboratories,
  • % inhibition 1 - average cpm (test compound) - average cpm (blank) average cpm (control) - average cpm (blank)
  • IC 50 is defined as that concentration of compound which inhibits 50% of specific hydrolysis of [ 3 H]cAMP to [ 3 H]5'AMP.
  • TNF TNF
  • EDTA ethylenediaminetetraacetic acid
  • Mononuclear cells are isolated by FicolF/Hypaque and washed three times in incomplete HBSS. Cells are resuspended in a final concentration of 1 x 10 6 cells per ml in pre-warmed RPMI (containing 5% FCS, glutamine, pen/step and nystatin). Monocytes are plated as 1 x 10 6 cells in 1.0 ml in 24-well plates. The cells are incubated at 37°C (5% carbon dioxide) and allowed to adhere to the plates for 2 hours, after which time non-adherent cells are removed by gentle washing.
  • 37°C 5% carbon dioxide
  • Test compounds (10 ⁇ l) are then added to the cells at 3-4 concentrations each and incubated for 1 hour.
  • LPS (10 ⁇ l) is added to appropriate wells. Plates are incubated overnight (18 hrs) at 37°C.
  • TNF was analyzed by a sandwich ELISA (R&D Quantikine Kit). IC 50 determinations are made for each compound based on linear regression analysis.
  • Pharmaceutically-acceptable acid addition salts of the compounds of this invention include, but are not limited to, those formed with HCI, HBr, HN0 3 , H 2 S0 4 , H 3 P0 4 , CH 3 SO 3 H, p-CH 3 C 6 H 4 S0 3 H, CH 3 C0 2 H, gluconic acid, tartaric acid, maleic acid and succinic acid.
  • Pharmaceutically-acceptable cationic salts of the compounds of this invention of formula I wherein R 4 is C0 2 R 6 and R 6 is hydrogen include, but are not limited to, those of sodium, potassium, calcium, magnesium, ammonium, N,N'- dibenzylethylenediamine, N-methylglucamine (meglumine), ethanolamine and diethanolamine.
  • oral dosages of the compounds of formula I and the pharmaceutically acceptable salts thereof are generally in the range of from 0.1-100 mg daily for an average adult patient (70 kg).
  • individual tablets or capsules contain from 0.1 to 50 mg of active compound, in a suitable pharmaceutically acceptable vehicle or carrier.
  • Dosages for intravenous administration are typically within the range of 0.1 to 10 mg per single dose as required.
  • the dosage is generally formulated as a 0.1 to 1% (w/v) solution.
  • the active compound will be administered orally or parenterally at dosages between about 0.1 and 25 mg/kg body weight of the subject to be treated per day, preferably from about 0.3 to 5 mg/kg. However, some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject.
  • the active compounds of the present invention can be administered alone, but will generally be administered in an admixture with a pharmaceutical diluent or carrier selected with regard to the intended route of administration and standard pharmaceutical practice.
  • a pharmaceutical diluent or carrier selected with regard to the intended route of administration and standard pharmaceutical practice.
  • they may be administered orally in the form of tablets containing such excipients as starch or lactose, or in capsules or ovales either alone or in admixture with excipients, or in the form of elixirs or suspensions containing flavoring or coloring agents.
  • They may be injected parenterally; for example, intravenously, intramuscularly or subcutaneously.
  • parenteral administration they are best used in the form of a sterile aqueous solution which may contain other substances; for example, enough salts or glucose to make the solution isotonic.
  • compositions comprising a compound of the formula I and the pharmaceutically acceptable salts thereof together with a pharmaceutically acceptable diluent or carrier.
  • the resulting dry solid was suspended in cold ether (ice-bath) and treated with oxalyl chloride (31 ⁇ l, 0.35 mmole) and anhydrous N,N-dimethylformamide (1 drop). After stirring for 1 hour the valatiles are removed under reduced pressure, and the crude residue was dissolved in dry tetrahydrofuran. The resulting solution was added dropwise to briskly stirred ammonium hydroxide at 0°C. After warming to ambient temperature over 2 hours the reaction mixture was concentrated under reduced pressure until a yellow solid begins to precipitate. At this time the mixture was diluted with water to approximately 100 ml and filtered, and the precipitate was washed with water to give 81 mg of the title compound.
  • 26 iso- 4-methoxy 3,4- 145-147° 61.40, 4.92, 9.76 61.29, 4.81 , 9.53 propyl phenyl dichloro phenyl
  • Recrystallizing solvents a 5% Ethyl acetate/petroleum ether. b Isopropyl ether. c Ethyl acetate/hexane. d Ethyl ether. "5% Ethyl acetate/pentane. 'Pentane.
  • Example 65 1 -cvclopentyl-3-ethyl-6-cvclopropylmethyl-7-oxo-4.5.6.7-tetrahydro-1 H- pyrazolo[3,4-clpyridine
  • a solution of 1-cyclopentyl-3-ethyl-7-oxo-4,5,6,7-tetrahydro-1 H-pyrazolo[3,4- c]pyridine (0.21 grams, 0.92 mmoles) in THF (5 ml) is treated with 60% sodium hydride in mineral oil (40 mg, 1.01 mmoles).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP94916370A 1993-07-06 1994-06-16 Bicyclic tetrahydro pyrazolopyridines Withdrawn EP0707585A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8829293A 1993-07-06 1993-07-06
US88292 1993-07-06
PCT/IB1994/000156 WO1995001980A1 (en) 1993-07-06 1994-06-16 Bicyclic tetrahydro pyrazolopyridines

Publications (1)

Publication Number Publication Date
EP0707585A1 true EP0707585A1 (en) 1996-04-24

Family

ID=22210524

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94916370A Withdrawn EP0707585A1 (en) 1993-07-06 1994-06-16 Bicyclic tetrahydro pyrazolopyridines

Country Status (20)

Country Link
EP (1) EP0707585A1 (xx)
JP (1) JP2944048B2 (xx)
KR (1) KR100228949B1 (xx)
CN (1) CN1048015C (xx)
AU (1) AU695301B2 (xx)
BR (1) BR9406946A (xx)
CA (1) CA2166721C (xx)
CZ (1) CZ3696A3 (xx)
EG (1) EG20513A (xx)
FI (1) FI943208L (xx)
HU (1) HUT74170A (xx)
IL (1) IL110175A (xx)
MX (1) MX9405132A (xx)
NO (1) NO305029B1 (xx)
NZ (1) NZ266525A (xx)
PL (1) PL312426A1 (xx)
RU (1) RU2131876C1 (xx)
TW (1) TW316904B (xx)
WO (1) WO1995001980A1 (xx)
ZA (1) ZA944844B (xx)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ120097A3 (cs) * 1994-10-20 1998-01-14 Pfizer Inc. Bicyklické tetrahydropyrazolopyridiny a farmaceutické prostředky na jejich bázi
EP0837860B1 (en) * 1995-06-06 2002-03-20 Pfizer Inc. TRICYCLIC 5,6-DIHYDRO-9H-PYRAZOLO(3,4-c]-1,2,4-TRIAZOLO(4,3-ALPHA]PYRIDINES
AP932A (en) * 1996-08-26 2001-02-02 Pfizer Tricyclic 5,6-dihydro-9H-pyrazolo (3,4c)-1,2,4,-triazolo (4,3-a) pyridines.
KR100338610B1 (ko) * 1996-09-04 2002-05-27 디. 제이. 우드, 스피겔 알렌 제이 인다졸 유도체 및 포스포디에스터라제 (pde) 유형 iv 및 종양괴사인자 (tnf) 생산의 억제제로서 그의 용도
EP1140941B1 (en) * 1998-12-23 2004-10-20 Bristol-Myers Squibb Pharma Company Nitrogen containing heterobicycles as factor xa inhibitors
US6858616B2 (en) 1998-12-23 2005-02-22 Bristol-Myers Squibb Pharma Company Nitrogen containing heterobicycles as factor Xa inhibitors
US6326495B2 (en) 1999-04-30 2001-12-04 Pfizer Inc. Process for preparing 8-cyclopentyl-6-ethyl-3-[substituted]-5,8-dihydro-4H-1,2,3a,7,8-pentaaza-as-indacenes and intermediates useful therein
TR200909479T2 (tr) 1999-08-21 2012-02-21 Nycomed Gmbh Sinerjistik kombinasyon.
TWI243055B (en) * 2000-04-13 2005-11-11 Nippon Zoki Pharmaceutical Co Pharmaceutical composition for use in treatment of dermatitis
NZ524475A (en) * 2000-08-10 2004-11-26 Pharmacia Italia S Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US6960595B2 (en) * 2001-03-23 2005-11-01 Bristol-Myers Squibb Pharma Company 5-6 to 5-7 Heterobicycles as factor Xa inhibitors
US6706730B2 (en) 2001-04-18 2004-03-16 Bristol-Myers Squibb Pharma Company 1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-ones as factor Xa inhibitors
US6750225B2 (en) 2001-04-18 2004-06-15 Bristol-Myers Squibb Pharms Company 1,4,5,6-tetrahydropyrazolo-[3,4,-c]-pyridin-7-ones useful as factor Xa inhibitors
US7902179B2 (en) 2001-04-26 2011-03-08 Ajinomoto Co., Inc. Heterocyclic compounds
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
PT1611131E (pt) 2003-02-27 2010-12-20 Palau Pharma Sa Derivados de pirazolopiridina
US7135469B2 (en) * 2003-03-18 2006-11-14 Bristol Myers Squibb, Co. Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors
MXPA05010373A (es) 2003-04-01 2005-12-05 Applied Research Systems Inhibidores de fosfodiesterasas en infertilidad.
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
DE102005031580A1 (de) * 2005-07-06 2007-01-11 Aicuris Gmbh & Co. Kg Substituierte Sulfolanylpyrazole und ihre Verwendung
PE20081889A1 (es) * 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2998314B1 (en) 2007-06-04 2020-01-22 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012118972A2 (en) 2011-03-01 2012-09-07 Synegy Pharmaceuticals Inc. Process of preparing guanylate cyclase c agonists
AU2014218599C1 (en) 2013-02-25 2018-09-06 Bausch Health Ireland Limited Guanylate cyclase receptor agonists for use in colonic cleansing
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CN113388007A (zh) 2013-06-05 2021-09-14 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
KR20220147691A (ko) 2013-08-09 2022-11-03 알데릭스, 인코포레이티드 인산염 수송을 억제하기 위한 화합물 및 방법
CN110357888A (zh) * 2018-04-09 2019-10-22 南京药捷安康生物科技有限公司 杂环磷酸二酯酶抑制剂及其用途
US20200368223A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Methods for inhibiting phosphate transport

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3365459A (en) * 1964-09-08 1968-01-23 Ciba Geigy Corp Certain tetrahydro pyrazolo-pyridine and pyrazolo-piperidine derivatives
FR1463883A (fr) * 1964-09-08 1966-07-22 Ciba Geigy Procédé de préparation de triaza-composés bicycliques
US3340269A (en) * 1964-09-08 1967-09-05 Ciba Geigy Corp 1-substituted 4-acyl-2, 3-dioxo-piperidine
US5356897A (en) * 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9501980A1 *

Also Published As

Publication number Publication date
AU6805794A (en) 1995-02-06
CZ3696A3 (en) 1997-06-11
EG20513A (en) 1999-06-30
CA2166721C (en) 1999-07-27
IL110175A0 (en) 1994-10-07
BR9406946A (pt) 1996-08-06
NO960056L (no) 1996-01-05
KR960703852A (ko) 1996-08-31
IL110175A (en) 2000-01-31
HU9503934D0 (en) 1996-03-28
RU2131876C1 (ru) 1999-06-20
KR100228949B1 (ko) 1999-11-01
TW316904B (xx) 1997-10-01
CN1048015C (zh) 2000-01-05
PL312426A1 (en) 1996-04-29
NO960056D0 (no) 1996-01-05
NZ266525A (en) 1997-10-24
MX9405132A (es) 1995-01-31
FI943208L (fi) 1995-01-07
FI943208A0 (fi) 1994-07-05
CA2166721A1 (en) 1995-01-19
JP2944048B2 (ja) 1999-08-30
JPH08507084A (ja) 1996-07-30
ZA944844B (en) 1996-01-05
AU695301B2 (en) 1998-08-13
HUT74170A (en) 1996-11-28
CN1129940A (zh) 1996-08-28
NO305029B1 (no) 1999-03-22
WO1995001980A1 (en) 1995-01-19

Similar Documents

Publication Publication Date Title
EP0707585A1 (en) Bicyclic tetrahydro pyrazolopyridines
AU702105B2 (en) Bicyclic tetrahydro pyrazolopyridines and their use as medicaments
US5508300A (en) Dihydro pyrazolopyrroles, compositions and use
US6262040B1 (en) Indazole derivatives and their use as inhibitors of phosphodiesterase (PDE) type IV and the production of tumor necrosis factor (TNF)
KR100339935B1 (ko) 치환된 인다졸 유도체, 및 포스포디에스테라제 4형 및 종양괴사 인자 형성의 억제제로서의 그의 용도
WO2001019802A1 (fr) Composes cycliques aromatiques azotes a six elements
KR20000022516A (ko) 치환된 인다졸 유도체 및 포스포디에스테라제 4형 및 종양 괴사인자 억제제로서 그의 용도
EP0816357B1 (en) Substituted indazole derivatives
WO1997047622A1 (fr) Inhibiteurs de production de cytokines, composes triazepine et intermediaires correspondants
CA2438294C (en) Pyridopyrimidine or naphthyridine derivative
EP0837860B1 (en) TRICYCLIC 5,6-DIHYDRO-9H-PYRAZOLO(3,4-c]-1,2,4-TRIAZOLO(4,3-ALPHA]PYRIDINES
JP2005509626A (ja) マトリックスメタロプロテアーゼ−１３阻害剤としてのアルキニル化縮合環ピリミジン化合物
JP2004083587A (ja) 医薬組成物
AU9240298A (en) Bicyclic tetrahydro pyrazolopyridines and their use as medicaments
AP932A (en) Tricyclic 5,6-dihydro-9H-pyrazolo (3,4c)-1,2,4,-triazolo (4,3-a) pyridines.
CA2201728A1 (en) Bicyclic tetrahydro pyrazolopyridines and their use as medicaments

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19951219

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 19961223

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20000503